INCY Incyte Corporation

106.47
+3.82  (+4%)
Previous Close 102.65
Open 102.82
52 Week Low 62.48
52 Week High 110.25
Market Cap $23,143,751,647
Shares 217,373,454
Float 183,947,900
Enterprise Value $21,071,207,053
Volume 1,439,053
Av. Daily Volume 1,612,465
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Jakafi
Myelofibrosis
Approved
Approved
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Baricitinib (NIAID Adaptive Treatment Trial)
COVID-19 Coronavirus
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Tafasitamab (MOR208/XmAb5574)
Relapsed or refractory diffuse large B cell lymphoma
PDUFA priority review
PDUFA priority review
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Ruxolitinib - REACH 2
Steroid-refractory acute GVHD (Graft versus host disease)
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Retifanlimab INCMGA0012
Anal cancer
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Baricitinib
Alopecia Areata
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Ruxolitinib - TRuE-AD1
Atopic dermatitis
NDA Filing
NDA Filing
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
INCB54828 Pemigatinib (FIGHT-201)
Bladder cancer
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Parsaclisib INCB50465 (CITADEL-204)
Marginal zone lymphoma
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Parsaclisib INCB50465 (CITADEL-203)
Follicular lymphoma
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Parsaclisib INCB50465 (CITADEL-205)
Mantle cell lymphoma
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Baricitinib
Systemic lupus erythematosus (SLE)
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Ruxolitinib - TRuE-V
Vitiligo
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Itacitinib - GRAVITAS-309
Chronic Graft-Versus-Host Disease
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Pelareorep and retifanlimab (INCMGA00012) - IRENE
Triple-negative breast cancer.
Phase 2
Phase 2
Phase 2 trial to be initiated.
INCB54828 (FIGHT-203)
MPN (Myeloproliferative Neoplasms)
Phase 2
Phase 2
Phase 2 interim data released at ASH 2018.
Capmatinib
Non-small cell lung cancer
Approved
Approved
FDA Approval announced May 6, 2020.
Pemigatinib
Cholangiocarcinoma
Approved
Approved
FDA Approval announced April 17, 2020.
Ruxolitinib (Jakafi)
COVID-19 associated cytokine storm
Phase 3
Phase 3
Phase 3 initiation announced April 17, 2020.
Itacitinib - GRAVITAS-301
Treatment-naïve acute GVHD
Phase 3
Phase 3
Phase 3 trial did not meet primary endpoint - January 2, 2020.
Pemigatinib (FIGHT-302)
Cholangiocarcinoma - first line
Phase 3
Phase 3
Phase 3 initiation of dosing announced June 4, 2019.
Ruxolitinib, Lenalidomide, and Methylprednisolone
Relapsed/Refractory Multiple Myeloma
Phase 1
Phase 1
Phase 1 oral abstract June 1, 2018, 2:45p.m. CT. Abstract 8005.
INCB001158
Solid tumors
Phase 1/2
Phase 1/2
Phase 1/2 data at ESMO 2019 noted - 7% PR rate.
Ruxolitinib (RESET)
Essential thrombocythemia
Phase 3
Phase 3
Recruitment has been discontinued - February 13, 2020.
Baricitinib
Atopic dermatitis
Phase 3
Phase 3
Phase 3 BREEZE-AD5 trial met primary endpoint - January 30, 2020.
INCB024360 + Epacadostat
Solid tumors
Phase 1/2
Phase 1/2
Phase 1/2 ongoing.
INCB50465 and ruxolitinib
Myelofibrosis
Phase 2
Phase 2
Phase 2 data presented at ASH December 2, 2018.
Epacadostat with Keytruda - (ECHO-206)
Cancer - solid tumors
Phase 1/2
Phase 1/2
Phase 1/2 enrolling.
Epacadostat with Opdivo (nivolumab) - (ECHO-207)
Solid tumors
Phase 1/2
Phase 1/2
Phase 1/2 initiated April 2017.
Epacadostat with Keytruda - ECHO-202/KEYNOTE-037
NSCLC, RCC, Triple-Negative Breast, Ovarian, Urothelial Carcinoma, Solid Tumors
Phase 1/2
Phase 1/2
Phase 1/2 various presentations at ASCO June 5, 2017. Updated data at ESMO Saturday, 9 September 2017 showed ORR 56% in melanoma patients.
Epacadostat with pembrolizumab (ECHO-303)
Bladder cancer
Phase 3
Phase 3
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-304)
Head & neck cancer
Phase 3
Phase 3
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-307)
Bladder cancer
Phase 3
Phase 3
Phase 3 enrollment to be discontinued.
Epacadostat with nivolumab (ECHO-309)
Non-small cell lung cancer (NSCLC)
Phase 3
Phase 3
Phase 3 enrollment to be discontinued.
Epacadostat with nivolumab (ECHO-310)
Head and neck cancer
Phase 3
Phase 3
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-306)
Non-small cell lung cancer (NSCLC)
Phase 2
Phase 2
Phase 3 trial to be converted into randomized Phase 2 trial.
Epacadostat with pembrolizumab (ECHO-305)
Non-small cell lung cancer (NSCLC)
Phase 3
Phase 3
Phase 3 trial to be converted into randomized Phase 2 trial.
Epacadostat with pembrolizumab (ECHO-302)
Renal cancer
Phase 3
Phase 3
Phase 3 enrollment to be discontinued.
Ruxolitinib
Graft versus host disease
Approved
Approved
FDA approval announced May 24, 2019.
INCB50465 (CITADEL-202)
Diffuse large B cell lymphoma
Phase 2
Phase 2
Phase 2 trial to be discontinued - noted June 21, 2018.
Baricitinib
Rheumatoid arthritis
Approved
Approved
CRL received April 14, 2017. NDA resubmitted. Approval announced for low dose only - June 1, 2018.
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Phase 3
Phase 3
Phase 3 trial did not meet primary endpoint - noted April 6, 2018.
Epacadostat with durvalumab
Non-small cell lung cancer (NSCLC)
Phase 3
Phase 3
Phase 3 trial to commence 1H 2018.
Ruxolitinib - JANUS 1 and JANUS 2
Cancer - Pancreatic
Phase 3
Phase 3
Phase 3 trial discontinued due to lack of efficacy
Jakafi (ruxolitinib) (RELIEF)
Disease-related symptoms in patients with Polycythemia Vera
Phase 3
Phase 3
Endpoint not met, mid-2014
Ruxolitinib
Colorectal cancer
Phase 2
Phase 2
Phase 2 trial stopped January 2016 due to lack of efficacy
Jakafi (ruxolitinib) (RESPONSE)
Polycythemia Vera
Approved
Approved
Approved December 4, 2014.
Epacadostat with Keytruda
Bladder cancer
Phase 3
Phase 3
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
Phase 3
Phase 3
Phase 3 planned.
Epacadostat with Keytruda
Squamous cell carcinoma of the head and neck cancer
Phase 3
Phase 3
Phase 3 planned.
Epacadostat with Opdivo (nivolumab)
First-line head and neck cancer
Phase 3
Phase 3
Phase 3 trial planned for 2017.
Epacadostat with Opdivo (nivolumab)
First-line non-small cell lung cancer
Phase 3
Phase 3
Phase 3 trial planned for 2017.

Latest News

  1. - The approval of Tabrecta in Japan follows U.S. FDA approval earlier this year

    - Tabrecta is the third Incyte-discovered molecule to be approved by the MHLW

    - Novartis has exclusive worldwide development and commercialization rights to Tabrecta

    Incyte (NASDAQ:INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Tabrecta™ (capmatinib) for MET exon 14 skipping (METex14) mutation-positive advanced and/or recurrent unresectable non-small cell lung cancer (NSCLC). Tabrecta is approved for first-line and previously treated patients, regardless of prior treatment type.

    Tabrecta is the third Incyte-discovered medicine to receive approval in Japan. Novartis has exclusive worldwide development and commercialization…

    - The approval of Tabrecta in Japan follows U.S. FDA approval earlier this year

    - Tabrecta is the third Incyte-discovered molecule to be approved by the MHLW

    - Novartis has exclusive worldwide development and commercialization rights to Tabrecta

    Incyte (NASDAQ:INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Tabrecta™ (capmatinib) for MET exon 14 skipping (METex14) mutation-positive advanced and/or recurrent unresectable non-small cell lung cancer (NSCLC). Tabrecta is approved for first-line and previously treated patients, regardless of prior treatment type.

    Tabrecta is the third Incyte-discovered medicine to receive approval in Japan. Novartis has exclusive worldwide development and commercialization rights to Tabrecta. Approval of Tabrecta in Japan triggers a $20 million milestone payment to Incyte, and Incyte is also eligible to receive 12-14% royalties on global net sales of Tabrecta by Novartis.

    "We are grateful for the efforts of Novartis Pharma K.K. and MHLW and are delighted that this important, targeted treatment option will now become available to patients in Japan diagnosed with METex14 NSCLC," said Lothar Finke, M.D., Ph.D., Group Vice President, Head of Development and General Manager, Asia, Incyte. "This approval highlights the strength of the Incyte in-house discovery program, and our commitment to finding solutions for serious medical needs."

    The approval of Tabrecta is based on results from the pivotal GEOMETRY mono-1 study. In the METex14 population (n=97), the confirmed overall response rate was 68% (95% CI, 48-84) and 41% (95% CI, 29-53) among treatment-naive (n=28) and previously treated patients (n=69), respectively, based on the Blinded Independent Review Committee (BIRC) assessment per RECIST v1.1. In patients taking Tabrecta, the study also demonstrated a median duration of response of 12.6 months (95% CI, 5.5–25.3) in treatment-naive patients (19 responders) and 9.7 months (95% CI, 5.5-13.0) in previously treated patients (28 responders). The most common treatment-related adverse events (AEs) (incidence ≥20%) are peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite.

    About Tabrecta

    Tabrecta (capmatinib) is a kinase inhibitor that targets MET discovered by Incyte and licensed to Novartis in 2009. Under the terms of the Agreement, Incyte granted Novartis exclusive worldwide development and commercialization rights to capmatinib and certain back-up compounds in all indications. Incyte is eligible for a total of over $500 million in milestones as well as royalties of between 12-14% on global net sales by Novartis.

    About Incyte

    Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

    For more information on Incyte Biosciences Japan G.K., please visit Incyte.jp.

    Forward-Looking Statements

    Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding milestone payments or royalties Incyte may receive from Novartis relating to Tabrecta, contain predictions, estimates and other forward-looking statements.

    These forward-looking statements are based on the Company's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA; the Company's dependence on its relationships with its collaboration partners; the efficacy or safety of the Company's products and the products of the Company's collaboration partners; the acceptance of the Company's products and the products of the Company's collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended March 31, 2020. The Company disclaims any intent or obligation to update these forward-looking statements.

    Disclaimer

    The drug information contained herein is intended for the disclosure of Incyte corporate information and is not intended to advertise or promote any medicinal product, including those under development.

    View Full Article Hide Full Article
  2. Incyte (NASDAQ:INCY) has updated its presentation time at the following investor conference:

    • JMP Securities Hematology & Oncology Forum (Virtual) on Thursday, June 18, 2020, now at 3:00 p.m. (EDT).

    The presentation at the BMO Prescriptions for Success Healthcare Conference (Virtual) on Tuesday, June 23, 2020 at 1:30 p.m. (EDT) is unchanged.

    The presentations for both conferences will be webcast live and can be accessed at Investor.Incyte.com. Replays will be available for 30 days.

    About Incyte
    Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information…

    Incyte (NASDAQ:INCY) has updated its presentation time at the following investor conference:

    • JMP Securities Hematology & Oncology Forum (Virtual) on Thursday, June 18, 2020, now at 3:00 p.m. (EDT).

    The presentation at the BMO Prescriptions for Success Healthcare Conference (Virtual) on Tuesday, June 23, 2020 at 1:30 p.m. (EDT) is unchanged.

    The presentations for both conferences will be webcast live and can be accessed at Investor.Incyte.com. Replays will be available for 30 days.

    About Incyte

    Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

    View Full Article Hide Full Article
  3. - Content highlights Incyte's approach to business and environmental sustainability

    - Inaugural Sustainable Accounting Standards Board (SASB) Summary now available

    Incyte (NASDAQ:INCY) today announced that a new Global Responsibility section has been launched as part of Incyte.com. This section provides information on Incyte's long-term approach and commitment to building a sustainable business by helping patients in need, supporting its colleagues, giving back to its communities, reducing its impact on the environment and promoting ethical and responsible behavior.

    In addition, and as part of this newly available content, Incyte has also released its first annual Sustainable Accounting Standards Board (SASB) Summary as well as a summary…

    - Content highlights Incyte's approach to business and environmental sustainability

    - Inaugural Sustainable Accounting Standards Board (SASB) Summary now available

    Incyte (NASDAQ:INCY) today announced that a new Global Responsibility section has been launched as part of Incyte.com. This section provides information on Incyte's long-term approach and commitment to building a sustainable business by helping patients in need, supporting its colleagues, giving back to its communities, reducing its impact on the environment and promoting ethical and responsible behavior.

    In addition, and as part of this newly available content, Incyte has also released its first annual Sustainable Accounting Standards Board (SASB) Summary as well as a summary of 2019 Global Responsibility Highlights.

    "We are proud to have formalized our Global Responsibility initiative. The first phase of this project has been to improve our public disclosure of our ongoing environmental, social and governance (ESG) efforts," said Hervé Hoppenot, Chief Executive Officer, Incyte. "Our Executive Leadership team will set specific priorities and goals for the next phase of our Global Responsibility initiative, and we look forward to keeping you informed on our progress."

    To learn more, visit Incyte.com/Responsibility or contact the Incyte Global Responsibility team at .

    About Incyte

    Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

    Forward-Looking Statements

    Except for the historical information set forth herein, the matters set forth in this press release, as well as the materials referenced on our corporate website, Incyte.com, including statements regarding whether the Company will achieve its global responsibility goals set forth in these materials or build a sustainable business, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, which risks are detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2019 and its Form 10-Q for the quarter ended March 31, 2020. The Company disclaims any intent or obligation to update these forward-looking statements.

    # # #

    View Full Article Hide Full Article
  4. Incyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of June:

    • Goldman Sachs 41st Annual Global Healthcare Conference (Virtual) on Tuesday, June 9, 2020 at 8:00 am (EDT);
    • JMP Securities Hematology & Oncology Forum (Virtual) on Thursday, June 18, 2020 at 4:40 pm (EDT); and
    • BMO Prescriptions for Success Healthcare Conference (Virtual) on Tuesday, June 23, 2020 at 1:30 pm (EDT)

    The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

    About Incyte

    Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development…

    Incyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of June:

    • Goldman Sachs 41st Annual Global Healthcare Conference (Virtual) on Tuesday, June 9, 2020 at 8:00 am (EDT);
    • JMP Securities Hematology & Oncology Forum (Virtual) on Thursday, June 18, 2020 at 4:40 pm (EDT); and
    • BMO Prescriptions for Success Healthcare Conference (Virtual) on Tuesday, June 23, 2020 at 1:30 pm (EDT)

    The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

    About Incyte

    Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

    View Full Article Hide Full Article
  5. Incyte (NASDAQ:INCY) announced today that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference (held virtually) on Tuesday, June 9, 2020 at 8:00 a.m. ET.

    The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

    About Incyte

    Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

    Incyte (NASDAQ:INCY) announced today that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference (held virtually) on Tuesday, June 9, 2020 at 8:00 a.m. ET.

    The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

    About Incyte

    Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

    View Full Article Hide Full Article
View All Incyte Corporation News